Comparative Immunogenicity and Reactogenicity of Heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or MRNA-1273-boosting with Homologous COVID-19 Vaccine Regimens

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Aug 11

PMID 35953492

Authors

Verena Klemis

Tina Schmidt

David Schub

Janine Mihm

Stefanie Marx

Amina Abu-Omar

Laura Ziegler

Franziska Hielscher

Candida Guckelmus

Rebecca Urschel

Stefan Wagenpfeil

Sophie Schneitler

Soren L Becker

Barbara C Gartner

Urban Sester

Martina Sester

Affiliations

Soon will be listed here.

Abstract

Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and homologous vaccination strategies in a convenience cohort of 331 healthy individuals. All regimens induce immunity to the vaccine antigen. Immunity after vaccination with ChAdOx1-nCoV-19 followed by either BNT162b2 (n = 66) or mRNA-1273 (n = 101) is equivalent to or more pronounced than homologous mRNA-regimens (n = 43 BNT162b2, n = 59 mRNA-1273) or homologous ChAdOx1-nCoV-19 vaccination (n = 62). We note highest levels of spike-specific CD8 T-cells following both heterologous regimens. Among mRNA-containing combinations, spike-specific CD4 T-cell levels in regimens including mRNA-1273 are higher than respective combinations with BNT162b2. Polyfunctional T-cell levels are highest in regimens based on ChAdOx1-nCoV-19-priming. All five regimens are well tolerated with most pronounced reactogenicity upon ChAdOx1-nCoV-19-priming, and ChAdOx1-nCoV-19/mRNA-1273-boosting. In conclusion, we present comparative analyses of immunogenicity and reactogenicity for heterologous vector/mRNA-boosting and homologous mRNA-regimens.

Citing Articles

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis.

De Voss C, Korompis M, Li S, Ateere A, McShane H, Stylianou E Front Immunol. 2025; 16:1540359.

PMID: 40018046 PMC: 11865049. DOI: 10.3389/fimmu.2025.1540359.

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.

Awadalla M, AlRawi H, Henawi R, Barnawi F, Alkadi H, Alyami A Front Immunol. 2025; 16:1526444.

PMID: 39911379 PMC: 11794813. DOI: 10.3389/fimmu.2025.1526444.

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial.

Gui Y, Cao Y, He J, Zhao C, Zheng W, Qian L Life Metab. 2025; 2(3):load019.

PMID: 39872015 PMC: 11749786. DOI: 10.1093/lifemeta/load019.

The Global Burden of Absenteeism Related to COVID-19 Vaccine Side Effects Among Healthcare Workers: A Systematic Review and Meta-Analysis.

Politis M, Rachiotis G, Mouchtouri V, Hadjichristodoulou C Vaccines (Basel). 2024; 12(10).

PMID: 39460361 PMC: 11511213. DOI: 10.3390/vaccines12101196.

Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?.

Favresse J, Tre-Hardy M, Gillot C, Cupaiolo R, Wilmet A, Beukinga I Heliyon. 2024; 10(16):e36116.

PMID: 39247272 PMC: 11379571. DOI: 10.1016/j.heliyon.2024.e36116.

References

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

Chemaitelly H, Yassine H, Benslimane F, Al Khatib H, Tang P, Hasan M . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021; 27(9):1614-1621. DOI: 10.1038/s41591-021-01446-y. View

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535. PMC: 8440177. DOI: 10.1038/s41591-021-01464-w. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881-891. PMC: 7894131. DOI: 10.1016/S0140-6736(21)00432-3. View

10.

Haas E, Angulo F, McLaughlin J, Anis E, Singer S, Khan F . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397(10287):1819-1829. PMC: 8099315. DOI: 10.1016/S0140-6736(21)00947-8. View

11.

Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

12.

Clemens S, Weckx L, Clemens R, Mendes A, Ramos Souza A, Silveira M . Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022; 399(10324):521-529. PMC: 8782575. DOI: 10.1016/S0140-6736(22)00094-0. View

13.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

14.

Hall V, Ferreira V, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K . Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022; 23(3):380-385. DOI: 10.1038/s41590-021-01126-6. View

15.

Ledo A, Schub D, Ziller C, Enders M, Stenger T, Gartner B . Elite athletes on regular training show more pronounced induction of vaccine-specific T-cells and antibodies after tetravalent influenza vaccination than controls. Brain Behav Immun. 2019; 83:135-145. DOI: 10.1016/j.bbi.2019.09.024. View

16.

Rydyznski Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D . Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020; 183(4):996-1012.e19. PMC: 7494270. DOI: 10.1016/j.cell.2020.09.038. View

17.

Schmidt T, Klemis V, Schub D, Schneitler S, Reichert M, Wilkens H . Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am J Transplant. 2021; 21(12):3990-4002. PMC: 8652989. DOI: 10.1111/ajt.16818. View

18.

Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M . Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021; 600(7890):701-706. DOI: 10.1038/s41586-021-04120-y. View

19.

Schub D, Klemis V, Schneitler S, Mihm J, Lepper P, Wilkens H . High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. JCI Insight. 2020; 5(20). PMC: 7605520. DOI: 10.1172/jci.insight.142167. View

20.

Chung H, He S, Nasreen S, Sundaram M, Buchan S, Wilson S . Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021; 374:n1943. PMC: 8377789. DOI: 10.1136/bmj.n1943. View